Sarepta Therapeutics Q2 2024 Adj. EPS $0.44 Beats $0.01 Estimate, Sales $362.931M Miss $391.406M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sarepta Therapeutics (NASDAQ:SRPT) reported Q2 2024 adjusted EPS of $0.44, significantly beating the analyst estimate of $0.01. However, the company's sales of $362.931 million missed the estimate of $391.406 million by 7.28%. Despite the miss, sales increased by 38.93% compared to the same period last year.
August 07, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sarepta Therapeutics reported a strong EPS beat but missed on sales estimates. The EPS of $0.44 beat the $0.01 estimate by a wide margin, while sales of $362.931 million missed the $391.406 million estimate by 7.28%. Sales increased by 38.93% YoY.
The significant EPS beat is likely to have a positive impact on the stock price in the short term, despite the sales miss. The strong YoY sales growth also adds a positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100